DNA alterations at proto-oncogene loci and their clinical significance in operable non-small cell lung cancer

Cancer. 1990 Aug 15;66(4):733-9. doi: 10.1002/1097-0142(19900815)66:4<733::aid-cncr2820660422>3.0.co;2-c.

Abstract

DNA from tumor samples of 54 patients with operable non-small cell lung cancer (NSCLC) was analyzed to determine whether proto-oncogene alterations could be correlated with the clinical behavior of lung cancer. Among seven proto-oncogenes tested, changes in the copy number of Ha-ras, c-myc and c-raf-1 were found in only seven tumors. Most of them were epidermoid carcinomas without lymph node involvement (N0). In spite of a localized disease with complete surgical resection, six of these patients relapsed within a mean disease-free interval (DFI) of only 6.5 months. There is a significant correlation between DNA alterations at proto-oncogene loci and clinical relapse within 12 months of surgical resection (P less than 0.025).

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blotting, Southern
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / surgery
  • DNA, Neoplasm / analysis*
  • Gene Amplification
  • Genes, ras
  • Humans
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Lung Neoplasms / surgery
  • Multicenter Studies as Topic
  • Neoplasm Staging
  • Oncogenes
  • Proto-Oncogenes*
  • Recurrence
  • Survival Rate

Substances

  • DNA, Neoplasm